


BIOSIMILARS

ARE BIOLOGIC MEDICINES THAT HELP DELIVER BETTER CARE FOR PEOPLE IN EMERGING COUNTRIES

NON-COMMUNICABLE DISEASES (NCDs), INCLUDING CANCER, ARE ON THE RISE - ESPECIALLY IN EMERGING MARKETS.¹

NCDs, also known as chronic diseases, include conditions such as cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes.¹

PERCENTAGE INCREASE OF CANCER INCIDENCE FROM 2022 TO 2050²




By 2050 cancer incidence will increase significantly faster in **Latin America** and **India** compared with **Europe** and **North America**². This is linked to economic development and changing lifestyles, leading to longer lives and higher late-life cancer risk.^{1,2}

BIOLOGICS ARE CUTTING-EDGE MEDICINES THAT HAVE SIGNIFICANTLY IMPROVED THE TREATMENT OF NCDs³




Biologics are derived from living organisms.⁴ They are highly complex molecules and more costly to produce than conventional medicines.^{3,5} Hence, they may remain out of reach for many.³

Access to new medicines, such as biologics, is more limited in emerging countries. In fact, new medicines make up only **0.1%** of total medicines used in emerging countries, which is over **20 times less** than in developed countries.³



BIOSIMILARS MAKE LIFE-SAVING MEDICINES MORE ACCESSIBLE AND AFFORDABLE IN EMERGING COUNTRIES³



Reduced access to treatments and care in emerging countries often leads to higher disease mortality rates compared to wealthier nations.⁶



Biosimilars are high-quality, highly similar versions of reference biologics. They are launched once the originator patent expires, which brings competition and increases the availability of biologic treatments.³

BIOSIMILARS ARE EFFECTIVE AND SAFE AND UNDERGO A RIGOROUS REGULATORY REVIEW



Biosimilars are developed through a high-quality scientific process that demonstrates they provide the same clinical benefits as the reference biologics.^{3,4}



6-9 years

The time it takes to demonstrate, through extensive testing, that a biosimilar delivers the same clinical benefits as the reference biologic.⁷

ABBOTT IS WORKING WITH EXPERTS TO EXPAND ACCESS TO BIOSIMILARS BY:



Facilitating regulatory pathways

- We've teamed up with the Americas Health Foundation and experts in cancer and health economics to tackle regulatory and policy challenges and streamline biosimilar regulatory pathways.
- This resulted in a **policy review** in *The Lancet Oncology* on streamlining biosimilars regulations to improve access to cancer treatment.⁹



Broadening access to scientific developments

- We are collaborating with local universities in Colombia on a '**Biosimilars Academy**', which provides healthcare professionals with the latest updates on biological treatments in oncology.
- In India, our '**Start Strong**' program includes workshops to share the latest scientific developments on osteoporosis management trends with healthcare professionals.



Improving care through insights and diagnostics

- We support the use of **real-world evidence (RWE)** and diagnostic tools for timely and accurate treatment.
- In India, we're improving access to **diagnostic scans** to promote early detection and treatment of bone density issues.



AT ABBOTT, WE ARE COMMITTED TO MAKING HIGH-QUALITY BIOSIMILARS MORE ACCESSIBLE TO PEOPLE FACING SERIOUS DISEASES IN EMERGING MARKETS, SO THAT THEY CAN GET AND STAY HEALTHY.

1. The Economist Intelligence Unit. The next pandemic? Non-communicable diseases in developing countries. 2017. Accessed September 24, 2024. https://impact.economist.com/perspectives/sites/default/files/The_next_pandemic.pdf

2. IQVIA Institute for Human Data Science. Global Oncology Trends. May 28, 2024. Accessed September 24, 2024. <https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2024>

3. Calamia M, Abraham I. The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countries. *Expert Opin Biol Ther.* 2023;23(8):653-657. doi:10.1080/14712598.2023.2247972

4. National Health Service England (NHS). What is a biosimilar medicine? September 12, 2023. Accessed September 24, 2024. <https://www.england.nhs.uk/long-read/what-is-a-biosimilar-medicine/>

5. Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. *Semin Arthritis Rheum.* 2022;52:151939. doi:10.1016/j.smarthit.2021.11.009

6. Higuchi M. United Nations (UN). UN Chronicle. Lifestyle diseases: access to chronic disease care in low- and middle-income countries. Accessed September 24, 2024. <https://www.un.org/en/chronicle/article/lifestyle-diseases-access-chronic-disease-care-low-and-middle-income-countries>

7. Ventola CL. Biosimilars: part 2: potential concerns and challenges for p&t committees. *PT.* 2013;38(6):329-335

8. Ott M, Dauben HP, Ahn J, et al. Value based healthcare and Health Technology Assessment for emerging market countries: joint efforts to overcome barriers. *Expert Rev Pharmacoecon Outcomes Res.* doi:10.1080/14737167.2024.2398482

9. Teran E, Gomez H, Hannois D, Lema M, Mantilla W, Rico-Restrepo M, McElwee E, Castro Sanchez N, Valdivieso N, Espinoza MA. Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspective. *Lancet Oncol.* 2022 Jul;23(7):e348-e358. doi:10.1016/S1470-2045(22)00121-8. PMID: 35772466.